跳至主要内容
临床试验/NCT03791658
NCT03791658已完成不适用

Assessment of Adherence to Controller Inhalation Medication in Asthma- and COPD Patients.

Universitair Ziekenhuis Brussel2 个研究点 分布在 1 个国家目标入组 141 人开始时间: 2019年1月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
141
试验地点
2
主要终点
Adherence to inhalation medication evaluated using the Test for the Adherence to Inhalers

研究概览

简要总结

The main aim of the study is to evaluate the adherence to controller inhalation medication in asthma and Chronic Obstructive Pulmonary Disease (COPD) in Universitair Ziekenhuis Brussel. Adherence will be assessed using the 12-question Test for the Adherence to Inhalers (TAI) yielding a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious). The aim of the study is also to compare the adherence between the 2 study subgroups (asthma and COPD patients). Several other factors which could influence the compliance of the patients will also be evaluated: age, sex, pack years, FEV1 (Forced Expiratory Volume 1), exacerbation history, symptom control, type of inhaler and number of inhalers. By identifying different patient and treatment characteristics that lead to non-adherence, future education efforts could be better targeted to these patients presenting the most important unmet need in terms of adherence.

详细描述

Adherence to the controller inhalation medication is an important component of asthma and COPD care. Good adherence to the prescribed medication is asthma patients is associated with better symptom control and improved lung function. Also, lower exacerbation rate and mortality risk, less healthcare utilisation, lower healthcare-associated costs and a better quality of life are linked with better adherence in asthma and COPD patients.

However, studies have shown that the adherence to therapy in chronically ill patients averages around 50%. In asthma patients the level of adherence varies between 30-70%, while compliance rate in COPD patients is around 20-60% (though the numbers vary). Adherence in asthma and COPD patients is thus generally low.

Adherence in these patients is measured in studies in different ways: electronic device monitoring, dispensing data, drug levels or several self-administered questionnaires, among others. Each technique has its own benefits and drawbacks. However, the easiest to use are the self-administered questionnaires. Although many of these exist, a particularly interesting questionnaire is the TAI (Test for the Adherence to Inhalers). It exists in 2 versions: a 10-question and a longer 12-question test. The 12 question TAI has 2 added questions, in which a healthcare professional evaluates the use of the inhaler by the patient. All 12 questions can then be used to identify different non-compliance behavioural patterns. The advantages of this questionnaire are therefore that it can be used for both asthma and COPD patients, that it is designed specifically for inhalation medication and that it not only measures adherence but also the type of non-compliance .

The main aim of the study is thus to evaluate the adherence to controller inhalation medication in asthma and COPD in Universitair Ziekenhuis Brussel. Adherence will be assessed using the 12-question TAI (Test for the Adherence to Inhalers). The aim of the study is also to compare the adherence between the 2 study subgroups (asthma and COPD patients). Several other factors which could influence the compliance of the patients will also be evaluated: age, sex, pack years, FEV1, exacerbation history, symptom control, type of inhaler and number of inhalers. By identifying different patient and treatment characteristics that lead to non-adherence, future education efforts could be better targeted to these patients presenting the most important unmet need in terms of adherence.

Patient recruitment will take place at the Universitair Ziekenhuis Brussel respiratory outpatient clinic. Before their scheduled appointment, patients they will be screened to participate in the study. Recruitment will start January 2019 until March 2019, or until the target number of patients is reached. On the day of their appointment, the participants will receive all necessary information about the study and the informed consent process from the principal investigator.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Asthmatics with treatment ≥ GINA step
  • COPD-patients , GOLD stage II-IV.

排除标准

  • No spirometry results available.
  • COPD patients not on long-acting bronchodilators.

研究组 & 干预措施

Asthmatics

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • FEV1 derived from the last spirometry (including spirometry performed on day of study visit).
  • GINA step (Global Initiative for Asthma).
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.
  • FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The Asthma Control Test (ACT)

干预措施: The 12-question TAI (Other)

Asthmatics

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • FEV1 derived from the last spirometry (including spirometry performed on day of study visit).
  • GINA step (Global Initiative for Asthma).
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.
  • FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The Asthma Control Test (ACT)

干预措施: Information from patients file (Other)

Asthmatics

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • FEV1 derived from the last spirometry (including spirometry performed on day of study visit).
  • GINA step (Global Initiative for Asthma).
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.
  • FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The Asthma Control Test (ACT)

干预措施: The Asthma Control Test (ACT) (Other)

COPD-patients

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • Pack Years
  • GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The COPD Assessment Test (CAT)

干预措施: The 12-question TAI (Other)

COPD-patients

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • Pack Years
  • GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The COPD Assessment Test (CAT)

干预措施: Information from patients file (Other)

COPD-patients

Other

From the patients file the following information will be collected by the investigators:

  • Age
  • Sex
  • Pack Years
  • GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)
  • Number of exacerbations in the year prior to the study.
  • The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
  • Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.

Patients will fill out:

  • The 12-question TAI-questionnaire (test for the adherence to inhalers)
  • The COPD Assessment Test (CAT)

干预措施: The COPD Assessment Test (CAT) (Other)

结局指标

主要结局

Adherence to inhalation medication evaluated using the Test for the Adherence to Inhalers

时间窗: 15 minutes

Level of adherence: high (=50 points), intermediate (between 46 and 49 points) or poor (\< or = 45 points) .

次要结局

  • Type of non-adherence/ Behavioural pattern (using TAI)(15 minutes)
  • Adherence in correlation to specific factors(15 minutes)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lisa Nicky Vancampenhout

Medical student

Universitair Ziekenhuis Brussel

研究点 (2)

Loading locations...

相似试验